Targeting AXL in NSCLC [0.03%]
靶向AXL以治疗非小细胞肺癌
Aubhishek Zaman,Trever G Bivona
Aubhishek Zaman
State-of-the-art cancer precision medicine approaches involve targeted inactivation of chemically and immunologically addressable vulnerabilities that often yield impressive initial anti-tumor responses in patients. Nonetheless, these respo...
Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges [0.03%]
MET第14外显子跳跃突变型肺癌的遗传特征、现有疗法及未来挑战
Toshio Fujino,Kenichi Suda,Tetsuya Mitsudomi
Toshio Fujino
MET exon 14 skipping mutation (MET∆ex14) is present about 3% of non-small cell lung cancers (NSCLCs). NSCLC patients with MET∆ex14 are characterized by an average age of over 70 years at diagnosis, a smoking history and a higher frequency...
Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations [0.03%]
莫博赛替尼(TAK-788)治疗EGFR 20号外显子插入突变非小细胞肺癌盘点
Shannon S Zhang,Viola W Zhu
Shannon S Zhang
The EGFR exon 20 insertion (EGFRex20ins) mutations are the third most common EGFR mutations seen in non-small cell lung cancer (NSCLC). More than 50 variants of EGFRex20ins mutations have been identified with A767_V769dupASV being the most ...
Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer [0.03%]
早期非小细胞肺癌的术前和术后免疫治疗
Nikhil Shukla,Nasser Hanna
Nikhil Shukla
Surgery or concurrent chemoradiation are standard of care treatments for patients with localized and locally advanced non-small cell lung cancer (NSCLC). While resection and chemoradiation are potentially curative therapies for early-stage ...
Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs) [0.03%]
免疫检查点抑制剂治疗非小细胞肺癌(NSCLC)的预后和预测生物标志物识别
Nicholas Giustini,Lyudmila Bazhenova
Nicholas Giustini
Immunotherapy plays a central role in the treatment of NSCLC and biomarkers predicting response to ICIs are valuable therapeutic tools. Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) is integral in therapy selection as its pos...
Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib [0.03%]
用于MET外显子14跳变型转移性非小细胞肺癌的新疗法——关注卡马替尼疗效
Aaron C Tan,Tracy J Loh,Xue Lin Kwang et al.
Aaron C Tan et al.
MET exon 14 (METex14) alterations are now an established therapeutically tractable target in non-small cell lung cancer (NSCLC). Recently reported trials of several MET tyrosine kinase inhibitors (TKI) in this patient population have demons...
Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling [0.03%]
通过联合靶向MEK/ERK信号来管理第三代EGFR酪氨酸激酶抑制剂获得性耐药的方法
Danlei Yu,Wen Zhao,Karin A Vallega et al.
Danlei Yu et al.
Although epidermal growth factor receptor (EGFR)-targeted therapy has improved clinical outcomes of patients with advanced non-small-cell lung cancer (NSCLC) carrying activating EGFR mutations, the development of acquired resistance to EGFR...
Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study [0.03%]
基于注册表的描述性研究：血清肿瘤标志物动力学作为非小细胞肺癌化疗免疫治疗和单纯免疫治疗维持阶段的预测生物标志物
David Lang,Wolfgang Haslinger,Kaveh Akbari et al.
David Lang et al.
Objective: To evaluate serum tumor markers (STM) as predictive biomarkers in advanced non-small cell lung cancer (NSCLC) treated with chemo-immunotherapy. ...
Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer [0.03%]
质子治疗治疗地面玻璃阴影型肺癌的临床疗效分析
Ichiro Nagata,Takashi Ogino,Takeshi Arimura et al.
Ichiro Nagata et al.
Purpose: Surgery is the standard treatment for early-stage non-small cell lung cancer (NSCLC), including ground-glass opacity (GGO)-type lung cancer. However, some patients are inoperable or refuse to undergo surgery. To ...
A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity [0.03%]
表皮生长因子受体酪氨酸激酶抑制剂在非小细胞肺癌中的当代文献综述及其毒性反应
Chung-Shien Lee,Sandhya Sharma,Emily Miao et al.
Chung-Shien Lee et al.
Mutations in the epidermal growth factor receptor (EGFR) are common amongst those with non-small cell lung cancer and represent a major factor in treatment decisions, most notably in the advanced stages. Small molecule tyrosine kinase inhib...